S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

SI-BONE (SIBN) Stock Forecast, Price & News

+0.58 (+4.49%)
(As of 05/20/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
657,908 shs
Average Volume
400,309 shs
Market Capitalization
$457.38 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive SIBN News and Ratings via Email

Sign-up to receive the latest news and ratings for SI-BONE and its competitors with MarketBeat's FREE daily newsletter.

SI-BONE logo


SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.


See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$90.15 million
Book Value
$3.61 per share


Net Income
$-56.57 million
Pretax Margin




Free Float
Market Cap
$457.38 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.20 out of 5 stars

Medical Sector

363rd out of 1,416 stocks

Surgical & Medical Instruments Industry

46th out of 138 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

SI-BONE (NASDAQ:SIBN) Frequently Asked Questions

Is SI-BONE a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SI-BONE in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SI-BONE stock.
View analyst ratings for SI-BONE
or view top-rated stocks.

When is SI-BONE's next earnings date?

SI-BONE is scheduled to release its next quarterly earnings announcement on Monday, August 1st 2022.
View our earnings forecast for SI-BONE

How were SI-BONE's earnings last quarter?

SI-BONE, Inc. (NASDAQ:SIBN) posted its quarterly earnings data on Monday, May, 9th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by $0.09. SI-BONE had a negative trailing twelve-month return on equity of 44.52% and a negative net margin of 67.00%. During the same quarter in the prior year, the company earned ($0.37) earnings per share.
View SI-BONE's earnings history

What guidance has SI-BONE issued on next quarter's earnings?

SI-BONE issued an update on its FY 2022 earnings guidance on Monday, May, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $106.00 million-$108.00 million, compared to the consensus revenue estimate of $107.35 million.

What price target have analysts set for SIBN?

7 equities research analysts have issued twelve-month price objectives for SI-BONE's stock. Their forecasts range from $25.00 to $36.00. On average, they anticipate SI-BONE's stock price to reach $31.57 in the next year. This suggests a possible upside of 133.9% from the stock's current price.
View analysts' price targets for SI-BONE
or view top-rated stocks among Wall Street analysts.

Who are SI-BONE's key executives?
SI-BONE's management team includes the following people:
  • Ms. Laura A. Francis MBA, CEO & Director (Age 55, Pay $879.74k) (LinkedIn Profile)
  • Mr. Anshul Maheshwari, Chief Financial Officer (Age 44, Pay $511.05k)
  • Mr. Anthony J. Recupero, Pres of Commercial Operations (Age 63, Pay $665.91k) (LinkedIn Profile)
  • Mr. Michael A. Pisetsky, Sr. VP of Operations & Admin., Sec. and Chief Legal Officer (Age 44) (LinkedIn Profile)
  • Dr. Scott A. Yerby, Sr. VP of Engineering & CTO (Age 54)
  • Mr. Joseph W. Powers, VP of Corp. Marketing (Age 62)
  • Dr. Daniel Joseph Cher, Sr. VP of Clinical & Regulatory Affairs (Age 57)
  • Dr. W. Carlton Reckling, Chief Medical Officer & VP of Medical Affairs (Age 60)
  • Mr. Nikolas F. Kerr, Sr. VP of Product, Strategy & Bus. Devel. (Age 50)
  • Ms. Joyce Goto, VP & Corp. Controller (Age 48)
What is Jeffrey Dunn's approval rating as SI-BONE's CEO?

10 employees have rated SI-BONE CEO Jeffrey Dunn on Glassdoor.com. Jeffrey Dunn has an approval rating of 41% among SI-BONE's employees. This puts Jeffrey Dunn in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of SI-BONE own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SI-BONE investors own include (HON), CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), Raytheon Technologies (RTX), Thermo Fisher Scientific (TMO), Verizon Communications (VZ), Alibaba Group (BABA), Cisco Systems (CSCO) and CSX (CSX).

When did SI-BONE IPO?

(SIBN) raised $84 million in an IPO on Wednesday, October 17th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is SI-BONE's stock symbol?

SI-BONE trades on the NASDAQ under the ticker symbol "SIBN."

Who are SI-BONE's major shareholders?

SI-BONE's stock is owned by a variety of retail and institutional investors. Top institutional investors include Brown Advisory Inc. (9.36%), BlackRock Inc. (8.00%), Champlain Investment Partners LLC (5.52%), Vanguard Group Inc. (4.68%), Gilder Gagnon Howe & Co. LLC (3.52%) and First Light Asset Management LLC (3.20%). Company insiders that own SI-BONE stock include Anshul Maheshwari, Anthony J Recupero, Anthony J Recupero, Gregory K Hinckley, Jeffrey W Dunn, Jeffrey W Dunn, Jeryl L Hilleman, John Gordon Freund, Laura Francis, Michael A Pisetsky and Michael A Pisetsky.
View institutional ownership trends for SI-BONE

Which major investors are selling SI-BONE stock?

SIBN stock was sold by a variety of institutional investors in the last quarter, including Summit Partners Public Asset Management LLC, Endurant Capital Management LP, State Street Corp, Bank of New York Mellon Corp, Champlain Investment Partners LLC, SG Americas Securities LLC, Tamarack Advisers LP, and Gilder Gagnon Howe & Co. LLC. Company insiders that have sold SI-BONE company stock in the last year include Anshul Maheshwari, Anthony J Recupero, Gregory K Hinckley, Jeffrey W Dunn, Jeryl L Hilleman, John Gordon Freund, Laura Francis, and Michael A Pisetsky.
View insider buying and selling activity for SI-BONE
or view top insider-selling stocks.

Which major investors are buying SI-BONE stock?

SIBN stock was purchased by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, Lisanti Capital Growth LLC, Penn Capital Management Company LLC, Wellington Management Group LLP, Next Century Growth Investors LLC, Brown Advisory Inc., Dimensional Fund Advisors LP, and Integral Health Asset Management LLC.
View insider buying and selling activity for SI-BONE
or or view top insider-buying stocks.

How do I buy shares of SI-BONE?

Shares of SIBN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SI-BONE's stock price today?

One share of SIBN stock can currently be purchased for approximately $13.50.

How much money does SI-BONE make?

SI-BONE has a market capitalization of $457.38 million and generates $90.15 million in revenue each year. The company earns $-56.57 million in net income (profit) each year or ($1.85) on an earnings per share basis.

How many employees does SI-BONE have?

SI-BONE employs 352 workers across the globe.

What is SI-BONE's official website?

The official website for SI-BONE is www.si-bone.com.

How can I contact SI-BONE?

SI-BONE's mailing address is 471 EL CAMINO REAL SUITE 101, SANTA CLARA CA, 95050. The company can be reached via phone at (408) 207-0700 or via email at [email protected].

This page was last updated on 5/22/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.